What's Happening?
Sebela Women's Health Inc. announced that the Phase 3 data publication of MIUDELLA, a hormone-free copper intrauterine system (IUS), has received the Daniel Mishell Jr., MD Outstanding Article Award at the Society of Family Planning Annual Meeting. The
award recognizes significant contributions to contraceptive research. MIUDELLA, approved by the FDA in February 2025, is designed to prevent pregnancy for up to three years and is expected to be available in the U.S. in the first half of 2026. The study was led by David K. Turok, MD, MPH, and Mitchell Creinin, MD, and highlighted the IUS's efficacy and safety.
Why It's Important?
The recognition of MIUDELLA's study underscores the importance of advancing contraceptive options that are hormone-free, offering women more choices in family planning. The award highlights the study's impact on the field of contraception, potentially influencing future research and development in this area. The FDA approval and upcoming availability of MIUDELLA could provide a new, long-term contraceptive option for women, addressing the need for diverse and effective birth control methods.
What's Next?
MIUDELLA is expected to be available to patients through trained healthcare providers in the U.S. by mid-2026. The focus will be on ensuring proper training for healthcare providers to minimize risks associated with improper insertion. The success of MIUDELLA could lead to further innovations in hormone-free contraceptive methods, potentially influencing guidelines and recommendations in family planning.
